10x Genomics, Inc. TXG Debt-to-equity

Debt-to-equity at other companies

TEC

Bio-TechneTECH

0.1×-0.1×

BrukerBRKR

0.8×-0.6×

IlluminaILMN

0.7×-0.2×

Agilent TechnologiesA

0.5×-0.1×

Quanterix CorporationQTRX

0.1×0.0×

Bio-Rad LaboratoriesBIO

0.1×-0.1×

FAQ

What is 10x Genomics, Inc.'s debt-to-equity?

10x Genomics, Inc. (TXG) reported debt-to-equity of 0.1× in Q2 2026.

How has 10x Genomics, Inc.'s debt-to-equity changed year-over-year?

10x Genomics, Inc.'s debt-to-equity decreased by 15.0% year-over-year, from 0.1× to 0.1×.

What is the long-term trend for 10x Genomics, Inc.'s debt-to-equity?

Over 5 years (2020 to 2025), 10x Genomics, Inc.'s debt-to-equity has grown at a 4.4% compound annual growth rate (CAGR), from 0.1× to 0.1×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.